Core Viewpoint - UBS downgraded the rating of Giant Bio (02367) from "Buy" to "Neutral" due to increased uncertainty in short-term revenue and profit outlook [1] Financial Projections - UBS reduced the earnings forecast for 2025 to 2027 by 25% to 41% [1] - Revenue projections for the same period were lowered by 20% to 36% [1] - Target price was significantly cut from HKD 79.5 to HKD 39.5 [1] Market Competition - The current market is experiencing intensified competition with the emergence of other skincare brands or products that offer more attractive pricing while also focusing on collagen restructuring [1] - Despite rapid product innovation, there is uncertainty regarding the success of new products in the coming year [1] Profitability Challenges - Maintaining high profitability is expected to be challenging in the context of increased competition and weakened marketing efficiency [1] - UBS anticipates a 2 to 3 percentage point erosion in net profit margin due to reduced marketing efficiency and operational deleveraging [1]

Investment Rating - The report assigns a "Buy" rating to the company with a target price of HKD 109.78, based on a PE valuation of 30 times for 2025 [4]. Core Insights - The company is a leading player in China's beauty and personal care industry, with a multi-brand matrix covering skincare, baby care, and hair care segments. The main brand, Han Shu, has rapidly expanded its presence on platforms like Douyin, achieving significant revenue growth [2][3]. - The company is expected to achieve revenue of CNY 67.93 billion in 2024, representing a year-on-year growth of 62.1%, with a net profit of CNY 7.81 billion, up 69.4% [14]. - The growth strategy is supported by a strong brand operation methodology, focusing on market-driven brand positioning, precise consumer targeting, and innovative marketing strategies [3][39]. Summary by Relevant Sections Company Highlights - The company has a multi-brand strategy with a focus on online sales, achieving nearly 93% online sales in the first half of 2025. The main brand, Han Shu, is projected to generate revenue of CNY 55.91 billion in 2024, a growth of 80.90% year-on-year [2]. - New brands like Yi Ye are experiencing rapid growth, with projected annual growth rates of 498% for 2023/2024 and 146% for the first half of 2025 [2]. Investment Logic - The company is expected to see significant growth in its three main segments: skincare, baby care, and hair care. Han Shu is projected to exceed CNY 10 billion in revenue within three years, while Yi Ye is expected to maintain a compound annual growth rate of over 50% [3]. - The baby care brand Yi Ye is leveraging a unique "medical research co-creation" model, while the hair care segment is expected to produce major brands through clear positioning and effective marketing strategies [3]. Profit Forecast, Valuation, and Rating - The forecasted EPS for 2025, 2026, and 2027 is CNY 2.68, CNY 3.33, and CNY 4.09 respectively, with a projected valuation of 24 times for 2026. The strong growth potential of the multi-brand strategy supports the "Buy" rating [4]. - The company is expected to achieve a return on equity (ROE) of 41.92% in 2025, indicating strong profitability [8].

Group 1 - The core viewpoint of the article indicates that 巨子生物 (Giant Bio) is experiencing significant sales pressure during the Double Eleven shopping festival, with a notable decline in sales for its Comfy brand on platforms like Tmall and Douyin, down 20% and 50% year-on-year respectively [1][1][1] - 招银国际 (CMB International) has revised its revenue growth forecast for the company for 2025/26 down to -3.5% and 13.6% due to short-term pressures on 可复美 (Kefumei) [1][1][1] - 中信证券 (CITIC Securities) has also adjusted its revenue and profit forecasts for 2025, citing the impact of the industry environment and corporate operational decisions on sales performance during Double Eleven [1][1][1] Group 2 - Despite the current challenges, the company possesses solid brand assets and operational structural highlights, indicating potential for future growth [1][1][1] - The company has a clear short, medium, and long-term strategy, with 可复美 aiming for a revenue target of 10 billion and a well-defined plan across products, operations, and channels [1][1][1] - 可丽金 (Kailijin) is expected to launch new products while undergoing brand rejuvenation, with the potential to create a second OTC blockbuster brand [1][1][1]

Core Viewpoint - The sales performance of Giant Bio (02367) has been negatively impacted during the Double Eleven shopping festival, leading to a decline in stock price and revenue forecasts for the upcoming years [1] Group 1: Sales Performance - Giant Bio's Comfy brand experienced a year-on-year sales decline of 20% on Tmall and 50% on Douyin during the Double Eleven period [1] - The company's sales pressure is attributed to underperformance in the DaBo sales channel [1] Group 2: Revenue Forecasts - CMB International has revised its revenue growth forecast for Giant Bio for the years 2025/26 down to -3.5% and 13.6% respectively [1] - CITIC Securities has also adjusted its revenue and profit forecasts for 2025, citing industry conditions and corporate operational decisions as influencing factors [1] Group 3: Future Outlook - Despite current challenges, Giant Bio has solid brand assets and structural operational highlights [1] - The company has a clear short, medium, and long-term strategy, with Comfy setting a revenue target of 10 billion and a clear plan for products, operations, and channels [1] - The company is also working on brand rejuvenation for its Keli brand while aiming to create a second OTC blockbuster brand [1]

Group 1 - The core viewpoint of the article indicates that due to the industry environment and corporate operational decisions, the sales of Giant Bio (02367) are under pressure during the Double Eleven shopping festival, leading to a downward revision of revenue and profit forecasts for 2025 [1] - The company has solid brand assets and there are structural highlights in its operations, suggesting potential for future growth despite current challenges [1] - Looking ahead, the company has a clear short, medium, and long-term strategy, with a goal to achieve 10 billion yuan in revenue and a well-defined plan for products, operations, and channels [1] Group 2 - The revenue and profit forecasts for 2025 have been adjusted to 5.49 billion yuan and 1.93 billion yuan respectively, with the net profit forecast adjusted to 1.98 billion yuan [1] - The company is assigned a target price of 44 HKD based on a 20x PE for 2026, maintaining a "Buy" rating [1] - The company plans to launch new products while undergoing brand rejuvenation, with the potential to create a second OTC blockbuster brand [1]

Core Viewpoint - CITIC Securities reports that due to industry environment and corporate operational decisions, Juzhi Biotechnology (02367) faces sales pressure during the Double Eleven shopping festival, leading to a downward revision of revenue and profit forecasts for 2025 [1] Group 1: Financial Forecasts - The revenue forecast for 2025 has been adjusted to 5.49 billion yuan, and the profit forecast has been revised to 1.93 billion yuan [1] - The adjusted net profit attributable to shareholders is projected to be 1.98 billion yuan [1] Group 2: Brand and Operational Insights - The company has solid brand assets and structural operational highlights, indicating potential for future growth [1] - The company has a clear short, medium, and long-term strategy, with a goal to achieve 10 billion yuan in revenue and a well-defined plan across products, operations, and channels [1] - Keli Jin is expected to undergo brand rejuvenation while launching new products, aiming to create a second OTC blockbuster brand [1] Group 3: Valuation and Rating - A price-to-earnings ratio of 20x is assigned for 2026, with a target price set at 44 HKD [1] - The rating is maintained at "Buy" [1]

近日(12月8日)，美妆科普博主麻瓜对言之有物50%玻色因面霜宣传图的问题提出质疑，在社交媒体引发了广泛关注和热议。 △图源：小红书 在这则笔记中，麻瓜爆料称，上述品牌50%玻色因面霜的产品详情页中，使用了来源于网络的外国人对比图进行产品功效展示，且图中人物"连发丝走向 都是一样的"，由此他对其功效宣称真实性产生了怀疑。 再结合宣传图中最后一行小字(上述人脸图片来源于网络，非功效测试人脸图)来看，对此麻瓜指出，这是品牌"故意拿网络图P图，夸大使用前后对比，再 到最后'藏'一个免责声明，说自己仅为网络P图，不是真的功效图"，以此逃避追责。 △图源：小红书 针对该事件，言安堂CEO赵国庆随即作出回应："详情页面不严谨，已经内部整改"，并表示"达人指出了问题，我们虚心接受，愿意接受行业监督。" △图源：小红书 而除盗用网络图这一问题外，在上述笔记发布及品牌方作出回应后不久，另一小红书博主"今天美妆又有瓜了"也针对此事提出了关于擦边球宣称、玻色因 数字游戏的两点质疑。 | | 擦边球宣称，P图造假 | | --- | --- | | | 以及玻色因数字游戏 | | 胶据查看 | | | 【产品编辑】 | 即日到时刻是 ...

天眼查App显示，近日，厦门星漾植萃化妆品有限公司成立，法定代表人为刘朝兴，注册资本3万人民 币，经营范围为一般项目：化妆品零售；互联网销售（除销售需要许可的商品）；化妆品批发；个人卫 生用品销售；日用杂品销售；针纺织品销售；服装服饰零售；鞋帽零售；日用品销售；日用家电零售； 灯具销售；日用百货销售；贸易经纪；母婴用品销售。（除依法须经批准的项目外，凭营业执照依法自 主开展经营活动）。 ...

天眼查App显示，近日，无锡呈光化妆品有限公司成立，法定代表人为史名册，注册资本10万人民币， 经营范围为一般项目：化妆品批发；化妆品零售；日用品批发；日用品销售；企业管理咨询；日用化学 产品销售；专业设计服务；图文设计制作；信息技术咨询服务；咨询策划服务；技术服务、技术开发、 技术咨询、技术交流、技术转让、技术推广；日用品出租；个人卫生用品销售；日用杂品销售（除依法 须经批准的项目外，凭营业执照依法自主开展经营活动）。 ...

证券代码：603630 证券简称：拉芳家化 公告编号：2025 – 052 拉芳家化股份有限公司 关于取消公司监事会、修订《公司章程》 及相关制度的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担个别及连带责任。 拉芳家化股份有限公司（以下简称"公司"或"本公司"）于2025年12月10日公司召开第五届董事会第六次 会议及第五届监事会第五次会议，审议通过了关于取消监事会并修订《公司章程》及相关制度的议案。 具体情况如下： 3、新增"控股股东和实际控制人"章节，明确规定控股股东及实际控制人的职责和义务； 4、根据相关监管规则及公司实际情况，相应修改公司章程若干条款； 5、根据公司实际经营需要，修改公司章程有关经营范围的条款。 鉴于本次修订所涉及的条目众多，如因新增或者减少条款导致原序号变化的，对序号进行相应调整，对 部分章节、条款及交叉引用所涉及序号变化的做相应调整，在不涉及其他实质性修订的前提下，不再逐 项列示。本次《公司章程》修订完成后，公司《监事会议事规则》相应废止；并同步修订《股东会议事 规则》和《董事会议事规则》，具体修订情 ...